- Takeda gains exclusive access to Halozyme's ENHANZE technology for vedolizumab.
- Vedolizumab is used for treating ulcerative colitis and Crohn's disease.
- IBD prevalence is expected to exceed 10 million globally by 2032.
- Halozyme receives upfront, milestone payments, and royalties from Takeda.
Collaboration Overview
Takeda has entered a global collaboration and license agreement with Halozyme Therapeutics, granting exclusive access to Halozyme's ENHANZE drug delivery technology for use with vedolizumab. This partnership aims to enhance the delivery and accessibility of vedolizumab, marketed as ENTYVIO, for treating ulcerative colitis and Crohn's disease.
IBD Treatment Focus
Ulcerative colitis and Crohn’s disease are the most common forms of inflammatory bowel disease (IBD), affecting millions worldwide. With IBD prevalence projected to surpass 10 million globally by 2032, there is a pressing need for innovative treatment solutions. This collaboration seeks to address these challenges by expanding Takeda's GI and Inflammation portfolio and broadening access to vedolizumab.
ENHANZE Technology
Halozyme's ENHANZE technology facilitates subcutaneous delivery of injected drugs, potentially improving patient experience by reducing time spent on therapy management. The technology has been commercially validated and used in over one million patient treatments across more than 100 global markets.
Financial Terms
Under the agreement, Takeda will make an upfront payment to Halozyme, along with potential future development and commercial milestone payments. Halozyme will also receive royalties on sales of products containing vedolizumab combined with ENHANZE.
